Drug Profile
MDNA 209
Alternative Names: MDNA209Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Medicenna Therapeutics
- Class Antineoplastics; Cytokines
- Mechanism of Action Interleukin 15 inhibitors; Interleukin 2 receptor antagonists; Interleukin receptor common gamma subunit inhibitors; Interleukin-2 receptor beta subunit modulators; Natural killer cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada
- 28 Apr 2021 No recent reports of development identified for preclinical development in Inflammation in Canada
- 08 Mar 2017 Preclinical trials in Autoimmune disorders in Canada (unspecified route) (Medicenna communication, March 2017)